Pathogenesis of Rosacea Anetta E

Total Page:16

File Type:pdf, Size:1020Kb

Pathogenesis of Rosacea Anetta E REVIEW Pathogenesis of Rosacea Anetta E. Reszko, MD, PhD; Richard D. Granstein, MD Rosacea is a chronic, common skin disorder whose pathogenesis is incompletely understood. An inter- play of multiple factors, including genetic predisposition and environmental, neurogenic, and microbial factors, may be involved in the disease process. Rosacea subtypes, identified in the recently published standard classification system by the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea, may in fact represent different disease processes, and identifying subtypes may allow investigators to pursue more precisely focused studies. New developments in molecular biology and genetics hold promise for elucidating the interplay of the multiple factors involved in the pathogen- esis of rosacea, as well as providing the bases for potential new therapies. osacea is a common, chronic skin disorder and secondary features needed for the clinical diagnosis primarily affecting the central and con- of rosacea. Primary features include flushing (transient vex areas of COSthe face. The nose, cheeks, DERM erythema), persistent erythema, papules and pustules, chin, forehead, and glabella are the most and telangiectasias. Secondary features include burn- frequently affected sites. Less commonly ing and stinging, skin dryness, plaque formation, dry affectedR sites include the infraorbital, submental, and ret- appearance, edema, ocular symptoms, extrafacial mani- roauricular areas, the V-shaped area of the chest, and the festations, and phymatous changes. One or more of the neck, the back, and theDo scalp. Notprimary Copy features is needed for diagnosis.1 The disease has a variety of clinical manifestations, Several authors have theorized that rosacea progresses including flushing, persistent erythema, telangiecta- from one stage to another.2-4 However, recent data, sias, papules, pustules, and tissue and sebaceous gland including data on therapeutic modalities of various sub- hyperplasia. Diagnosis of rosacea is based on clini- types, do not support this notion.5 A possible exception cally recognizable morphologic characteristics. However, is PPR, which may progress to the phymatous form. establishing precise, comprehensive diagnostic criteria is The National Rosacea Society Expert Committee on the difficult given the variety of clinical manifestations and Classification and Staging of Rosacea does not qualify the the lack of laboratory testing. rosacea subtypes as a spectrum from ETR to phymatous. The National Rosacea Society Expert Committee on the Rosacea subtype designation is of pivotal importance Classification and Staging of Rosacea defines and clas- because the therapeutic implications are different for sifies rosacea into the following clinical subtypes based various subtypes, and individual subtypes may in fact primarily on morphologic characteristics: erythematotel- represent pathologically distinct disease processes. angiectatic rosacea (ETR), papulopustular rosacea (PPR), To confirm diagnosis of rosacea, several diseases with phymatous rosacea, and ocular rosacea. similar cutaneous manifestations must be excluded. The National Rosacea Society Expert Committee on the These include polycythemia vera, connective tissue Classification and Staging of Rosacea identifies primary diseases (lupus erythematosus, dermatomyositis, and mixed connective tissue disease), carcinoid syndrome, Dr. Reszko is Resident in Dermatology, and Dr. Granstein is mastocytosis, photosensitivity, and allergic or irritant Professor of Dermatology, both at Department of Dermatology, contact dermatitis.6 Weill Cornell Medical College and New York-Presbyterian The pathogenesis of rosacea is complex and a subject of Hospital, New York. literature controversy. One hindering factor is that much The authors report no conflicts on interest in relation to of the data on rosacea were acquired before the National this article. Rosacea Society Expert Committee on the Classification 224 Cosmetic Dermatology® • april 2008 • VOL. 21 NO. 4 Copyright Cosmetic Dermatology 2010. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. Figure Not Available Online Figure Not Available Online Figure 1. Patient with erythematotelangiectatic rosacea displaying Figure 2. Patient with papulopustular rosacea displaying persis- persistent erythema and telangiectasias. Photograph courtesy of the tent central erythema with inflammatory papules and pustules in National Rosacea Society. a centrofacial distribution. Photograph courtesy of the National Rosacea Society. and Staging of Rosacea established strict diagnostic cri- teria. Moreover, various clinicalCOS subtypes of rosacea thatDERM be reported. Telangiectasias may be present but difficult may or may not represent the same clinicopathologic to distinguish from the erythematous background. irrita- process were studied simultaneously, possibly masking tion from external stimuli is not a constant feature; thus, true insights into rosacea. scaling and roughness are often absent. ROSACEA SUBTYDoPES NotPhymatous Copy Rosacea Erythematotelangiectatic Rosacea Phymatous rosacea is characterized by marked skin thick- The predominant sign of ETR is centrofacial flushing last- ening and edema with irregular surface nodularities of the ing more than 10 minutes, accompanied by a burning or nose, chin, forehead, ears, or eyelids (Figure 3). The skin stinging sensation with or without persistent erythema surface is often pitted with prominent sebaceous glands (Figure 1). The erythema usually spares the periocular and enlarged follicular openings. The clinical changes and submental skin but may involve the ears, neck, or result from extensive chronic inflammatory infiltration, upper part of the chest. Typically, patients with ETR will connective tissue hypertrophy with fibrosis, and marked possess skin with a fine texture without oiliness or the sebaceous gland hyperplasia.7 prominence of sebaceous glands. The erythematous areas Four distinct histologic variants may occur with rhi- of the face may appear rough with scales likely from nophyma (nasal phymatous rosacea): glandular, fibrous, chronic, low-grade inflammation. Telangiectasias are fibroangiomatous, and actinic. in addition to the nose, common but not essential for diagnosis.6 other commonly affected areas include the chin (gnatho- phyma), forehead (metophyma), ears (otophyma), and Papulopustular Rosacea eyelids (blepharophyma). PPR is characterized by persistent central erythema with inflammatory papules or pustules in a centrofacial dis- Ocular Rosacea tribution (Figure 2). This subtype may involve perioral The prevalence of ocular rosacea is the subject of debate, and perinasal areas. Prolonged periods of facial erythema with incidence rates of 3% to 58% reported in the litera- or flushing may lead to soft tissue edema lasting up to ture.8 Ocular manifestations may precede the cutaneous several days. Reports of patients developing solid, hard, signs of rosacea in approximately 20% of patients or they nonpitting edema of the forehead, glabella, upper eye- may develop concurrently with skin manifestations.9 lids, nose, and cheeks (Morbihan disease) have been Ocular manifestations include blepharitis, conjunctivi- described in the literature. A history of flushing may also tis, inflammation of the eyelids and meibomian glands, VOL. 21 NO. 4 • april 2008 • Cosmetic Dermatology® 225 Copyright Cosmetic Dermatology 2010. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. PATHOGENESIS OF ROSACEA Figure Not Available Online Figure Not Available Online Figure 3. Patient with phymatous rosacea displaying marked skin Figure 4. Patient with ocular rosacea displaying eyelid and thickening and edema with irregular surface nodularities of the nose conjunctival involvement. Photograph courtesy of the National (rhinophyma). Photograph courtesy of the National Rosacea Society. Rosacea Society. interpalpebral conjunctival hyperemia, corneal infiltrates, sebaceous gland hyperplasia and rhinophyma more often ulcers, and vascularizationCOS (Figure 4).9,10 in one series, DERM than women.12,15 conjunctival telangiectasias and irregularity of eyelid mar- Recent data from a large epidemiologic study of the gins were noted in 81% of patients with ocular rosacea.11 irish population, conducted with strict diagnostic cri- Meibomian gland dysfunction occurs in 78% of patients teria and using precise clinical definitions, showed no with ocular rosacea, leading first to decreased lipid significant difference in the prevalence of PPR between secretion and then to Doinflammation and Not foreign body males Copy and females and no significant association between sensation.11 Patients with rosacea frequently describe rosacea and UVR exposure and cutaneous solar damage.16 eye stinging or burning, dryness, irritation from light, or The study also revealed no correlation between family foreign body sensation. A potentially vision-threatening history of PPR and later development of PPR. complication of ocular rosacea is Staphylococcus aureus keratitis that may lead to corneal opacity, scarring, and PATHOGENESIS OF ROSACEA vision loss.12 Despite decades of study, the etiology of rosacea remains Ocular rosacea frequently occurs in association with unknown. The pathogenesis of rosacea is likely to be other rosacea subtypes, although there is no direct corre- multifactorial,
Recommended publications
  • Training Available: in 2012, Lorenzo Kunze, M.E
    2013 Derma-Lo - offers the 2013 Thermo-Lo - offers the reduction of: sun/age spot, milia, reduction of: sun/age spot, milia, telangiectasia / epidermal spider telangiectasia / epidermal spider veins, cherry hemangiomas, veins, cherry hemangiomas and Thermolysis (AC) and Electrolysis Thermolysis (AC) hair removal. (DC) hair removal. Also: active acne, acne scarring, sebaceous hyperplasia, and skin tags. Training Available: In 2012, Lorenzo Kunze, M.E. Includes: Hydro-Lo - treatment IN DENVER ONCE A MONTH developed Chromos, Inc. - which of fine lines and wrinkles, TRAINING AVAILABLE AT in Greek, can be interpreted as enlarged pore reduction, boosts YOUR LOCATION ASK ABOUT “color” or “light” – in essence, the penetration of product into COST without light we have no color. the skin and tightens loose skin. “Dedicated to Excellence” Also: select your choice of (1 of Continuing to provide a professional & positive attitude in the medical 2) LED’s – both are non invasive and aesthetic field. hand-held light probes: BLUE for CHROMOS, Inc. the treatment of acne or Lorenzo Kunze, M.E. Chromos strives to be a guiding INFRARED to increase collagen [email protected] “light” that assists medical and and elastin, Rosacea, increased www.DermaLo.com aesthetic professionals in finding healing properties, minor muscle www.Thermo-Lo.com and pursuing proper education and moderate joint pain. 888-499-8991 / 303-994-7236 and accurate knowledge. Lorenzo Kunze, M.E. Lorenzo is a true visionary - 40 years in the medical and aesthetic field Medical Electrologist / medical educator 1st non-medical professional to provide electrolysis treatments in an OR Treated over 20,000 patients - last 16 years 1st in the U.S.
    [Show full text]
  • Dermatology DDX Deck, 2Nd Edition 65
    63. Herpes simplex (cold sores, fever blisters) PREMALIGNANT AND MALIGNANT NON- 64. Varicella (chicken pox) MELANOMA SKIN TUMORS Dermatology DDX Deck, 2nd Edition 65. Herpes zoster (shingles) 126. Basal cell carcinoma 66. Hand, foot, and mouth disease 127. Actinic keratosis TOPICAL THERAPY 128. Squamous cell carcinoma 1. Basic principles of treatment FUNGAL INFECTIONS 129. Bowen disease 2. Topical corticosteroids 67. Candidiasis (moniliasis) 130. Leukoplakia 68. Candidal balanitis 131. Cutaneous T-cell lymphoma ECZEMA 69. Candidiasis (diaper dermatitis) 132. Paget disease of the breast 3. Acute eczematous inflammation 70. Candidiasis of large skin folds (candidal 133. Extramammary Paget disease 4. Rhus dermatitis (poison ivy, poison oak, intertrigo) 134. Cutaneous metastasis poison sumac) 71. Tinea versicolor 5. Subacute eczematous inflammation 72. Tinea of the nails NEVI AND MALIGNANT MELANOMA 6. Chronic eczematous inflammation 73. Angular cheilitis 135. Nevi, melanocytic nevi, moles 7. Lichen simplex chronicus 74. Cutaneous fungal infections (tinea) 136. Atypical mole syndrome (dysplastic nevus 8. Hand eczema 75. Tinea of the foot syndrome) 9. Asteatotic eczema 76. Tinea of the groin 137. Malignant melanoma, lentigo maligna 10. Chapped, fissured feet 77. Tinea of the body 138. Melanoma mimics 11. Allergic contact dermatitis 78. Tinea of the hand 139. Congenital melanocytic nevi 12. Irritant contact dermatitis 79. Tinea incognito 13. Fingertip eczema 80. Tinea of the scalp VASCULAR TUMORS AND MALFORMATIONS 14. Keratolysis exfoliativa 81. Tinea of the beard 140. Hemangiomas of infancy 15. Nummular eczema 141. Vascular malformations 16. Pompholyx EXANTHEMS AND DRUG REACTIONS 142. Cherry angioma 17. Prurigo nodularis 82. Non-specific viral rash 143. Angiokeratoma 18. Stasis dermatitis 83.
    [Show full text]
  • Rosacea: an Update
    REVIEW JONELLE K. MCDONNELL, MD KENNETH J. TOMECKI, MD Department of Dermatology, Cleveland Clinic Department of Dermatology, Cleveland Clinic Rosacea: An update • ABSTRACT | >1 OSACEA is a chronic and recurrent LAM inflammatory skin disease characterized Rosacea is a common inflammatory skin disease affecting by erythema, papules, pustules, telangiectasia, the central face of adults. Its etiology is unknown. Early and occasionally sebaceous hyperplasia, which diagnosis and appropriate treatment, usually with topical or primarily affects the central face. The disease systemic antibiotics or both, minimizes symptoms and helps evolves in stages and affects middle-aged to prevent complications. adults. Early diagnosis and thoughtful manage- ment help to control the disease and to mini- • KEY POINTS mize the patient's discomfort and emotional distress. Historically, rosacea has been a mis- Rosacea has a spectrum of cutaneous clinical findings: understood disorder, often attributed to alco- facial erythema, papules, pustules, telangiectasia, and holism and acne.1 rhinophyma. • INCIDENCE Common triggers are sunlight, stress, exposure to extreme Rosacea is a common and chronic disease that heat or cold, alcohol, hot beverages, and spicy foods. affects approximately 13 million Americans, or about 1 in 20 people. Because rosacea fre- Rosacea can resemble other diseases, including acne, quently affects people of northern European seborrheic dermatitis, systemic lupus erythematosus, and heritage, it is often called the "curse of the sarcoidosis. Celts."2 In contrast, it is rarely seen in dark- skinned individuals.3 In most patients, the Ocular involvement occurs in more than 50% of patients onset occurs between the ages of 30 and 50. with rosacea. The early stages affect women more often than men at a ratio of 3 to 1, but men more often Oral tetracycline and topical metronidazole are the develop disfiguring rhinophyma.
    [Show full text]
  • Pathological Investigation of Rosacea with Particular Regard Of
    CORE Metadata, citation and similar papers at core.ac.uk Provided by White Rose E-theses Online A Clinico-Pathological Investigation of Rosacea with Particular Regard to Systemic Diseases Dr. Mustafa Hassan Marai Submitted in accordance with the requirements for the degree of Doctor of Medicine The University of Leeds School of Medicine May 2015 “I can confirm that the work submitted is my own and that appropriate credit has been given where reference has been made to the work of others” “This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement” May 2015 The University of Leeds Dr. Mustafa Hassan Marai “The right of Dr Mustafa Hassan Marai to be identified as Author of this work has been asserted by him in accordance with the Copyright, Designs and Patents Act 1988” Acknowledgement Firstly, I would like to thank all the patients who participate in my rosacea study, giving their time and providing me with all of the important information about their disease. This is helped me to collect all of my study data which resulted in my important outcome of my study. Secondly, I would like to thank my supervisor Dr Mark Goodfield, consultant Dermatologist, for his continuous support and help through out my research study. His flexibility, understanding and his quick response to my enquiries always helped me to relive my stress and give me more strength to solve the difficulties during my research. Also, I would like to thank Dr Elizabeth Hensor, Data Analyst at Leeds Institute of Molecular Medicine, Section of Musculoskeletal Medicine, University of Leeds for her understanding the purpose of my study and her help in analysing my study data.
    [Show full text]
  • A Case of Steatocystoma Simplex Involving the Scalp
    230 A Case of Steatocystoma Simplex Involving the Scalp Dong Nyeok Hyun, M.D., Jong Hoon Won, M.D., Joon Soo Park, M.D., Hyun Chung, M.D. Department of Dermatology, School of Medicine, Catholic University of Daegu, Daegu, Korea Steatocystoma is a benign adnexal tumor originating from the pilosebaceous duct junction which can be classified into two groups (steatocystoma simplex and steatocystoma multiplex). Steatocystoma simplex, which presents as a solitary lesion, is very rare. Steatocystoma simplex occurs most commonly on the face and the case reported herein involving the scalp is extremely rare. A 49-year-old man presented for evaluation and treatment of a solitary papule on the right parietal scalp which had persisted for a period of 1 year. The histopathologic examination revealed a thin-walled cyst consisting of stratified squamous epithelium with hyaline cuticle that lacked a stratum granulosum. Based on clinical and histologic findings, we diagnosed this case as steatocystoma simplex of the scalp and report this rare case. (Ann Dermatol (Seoul) 20(4) 230∼232, 2008) Key Words: Scalp, Steatocystoma simplex INTRODUCTION CASE REPORT Steatocystoma simplex, first described as a dis- A 49-year-old man presented to our outpatient tinct entity by Brownstein1 in 1982, is an extremely clinic with an asymptomatic papule on the right rare benign adnexal tumor. The individual lesion of parietal scalp which had been present for about 1 steatocystoma simplex is usually identical with that year. The lesion had slowly enlarged a few months of steatocystoma multiplex, both clinically and ago. The physical examination revealed a skin- histologically, but is characterized by solitary, non- colored, deep-seated, soft cystic mass on his right heritable growth in adulthood1.
    [Show full text]
  • Cancer Immunoprevention: a Case Report Raising the Possibility of “Immuno-Interception” Jessica G
    CANCER PREVENTION RESEARCH | RESEARCH BRIEF Cancer Immunoprevention: A Case Report Raising the Possibility of “Immuno-interception” Jessica G. Mancuso1, William D. Foulkes1,2,3, and Michael N. Pollak1,2 ABSTRACT ◥ Immune checkpoint blockade therapy provides substan- or neoplastic lesions over a period of 19 years (mean tial benefits for subsets of patients with advanced cancer, 7.5 neoplasms/year, range 2–26) prior to receiving but its utility for cancer prevention is unknown. Lynch pembrolizumab immunotherapy as part of multi- syndrome (MIM 120435) is characterized by defective modality treatment for invasive bladder cancer. He not DNA mismatch repair and predisposition to multiple only had a complete response of the bladder cancer, but cancers. A variant of Lynch syndrome, Muir–Torre also was noted to have an absence of new cancers during a syndrome (MIM 158320), is characterized by frequent 22-month follow-up period. This case adds to the rationale gastrointestinal tumors and hyperplastic or neoplastic skin for exploring the utility of immune checkpoint blockade tumors. We report the case of a man with Muir–Torre forcancerprevention,particularlyforpatientswithDNA syndrome who had 136 cutaneous or visceral hyperplastic repair deficits. Introduction There is an obvious clinical need to reduce cancer incidence in patients with DNA repair deficits, and prophylactic surgery The clinically demonstrated utility of antiviral vaccines to is commonly employed. Clinical trials designed to evaluate reduce risk of virally initiated cancers represents a major strategies to reduce cancer incidence are challenging: in popu- success in cancer immunoprevention. There is interest in the lations where baseline risk is low, a large number of subjects and possibility that immunoprevention may also be useful where long follow-up periods are required.
    [Show full text]
  • Richtlijn Acneïforme Dermatosen
    Richtlijn Acneïforme dermatosen Richtlijn: Acneïforme dermatosen Colofon Richtlijn Acneïforme dermatosen © 2010, Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV) Postbus 8552, 3503 RN Utrecht Telefoon: 030-2823180 E-mail: [email protected] Alle rechten voorbehouden. Niets uit deze uitgave mag worden verveelvoudigd of openbaar worden gemaakt, in enige vorm of op enige wijze, zonder voorafgaande schriftelijke toestemming van de Nederlandse Vereniging voor Dermatologie en Venereologie. Deze richtlijn is opgesteld door een daartoe geïnstalleerde werkgroep van de Nederlandse Vereniging voor Dermatologie en Venereologie. De richtlijn is vervolgens vastgesteld in de algemene ledenvergadering. De richtlijn vertegenwoordigt de geldende professionele standaard ten tijde van de opstelling van de richtlijn. De richtlijn bevat aanbevelingen van algemene aard. Het is mogelijk dat deze aanbevelingen in een individueel geval niet van toepassing zijn. De toepasbaarheid en de toepassing van de richtlijnen in de praktijk is de verantwoordelijkheid van de behandelend arts. Er kunnen zich feiten of omstandigheden voordoen waardoor het wenselijk is dat in het belang van de patiënt van de richtlijn wordt afgeweken. 1 Versie 18-06-2010 WERKGROEP Prof. dr. P.C.M. van de Kerkhof, dermatoloog, voorzitter werkgroep Mw. J.A. Boer, huidtherapeut Drs. R.J. Borgonjen, ondersteuner werkgroep Dr .J.J.E. van Everdingen, dermatoloog Mw. M.E.M. Janssen, huidtherapeut Drs. M. Kerzman, NHG/huisarts Dr. J. de Korte, dermatopsycholoog Drs. M.F.E. Leenarts, dermatoloog i.o. Drs. M.M.D. van der Linden, dermatoloog Dr. J.R. Mekkes, dermatoloog Drs. J.E. Mooij, promovendus dermatologie Drs. L. van ’t Oost, dermatoloog i.o. Dr. V. Sigurdsson, dermatoloog Mw. C. Swinkels, hidradenitis patiënten vereniging/patiëntvertegenwoordiger Drs.
    [Show full text]
  • Price Sheet 01-01-21
    SERVICES & PRICING DERM CASH PRICES – FOR COSMETIC PROCEDURES Sebaceous Hyperplasia (Any #) . $150.00 Milia (Any #) . $100.00 Seborrheic Keratoses (Full Back Greater than 40) . $500.00 Seborrheic Keratoses (Half Back) . $250.00 Seborrheic Keratosis (Face) . $200.00 Lentigo (1-5 with TCA) . $150.00 Cherry Angiomas (Per Region) . $150.00 Benign Nevi (Per Spot) . $150.00 Skin Tags (1-15) . $100.00 Skin Tags (16 -25) . $150.00 Skin Tags (26 or more) . $250.00 AEROLASE CONDITION QTY FREQUENCY COST PER QTY. LENTIGO (1) 3 – 4 EVERY 3 – 4 WEEKS $50.00 LENTIGO (2-5) 3 – 4 EVERY 3 – 4 WEEKS $150.00 LENTIGOS (FULL FACE) 3 – 4 EVERY 3 – 4 WEEKS $250.00 FRECKLING/PIH 3 – 4 EVERY 3 – 4 WEEKS $275.00 MELASMA 4+ EVERY 3 – 4 WEEKS $250.00 ANGIOMA (1) 2 – 3 EVERY 3 – 4 WEEKS $50.00 ANGIOMAS (2-5) 2 – 3 EVERY 3 – 4 WEEKS $150.00 ANGIOMAS (FULL FACE) 2 – 3 EVERY 3 – 4 WEEKS $250.00 TELANGECTASIAS (FACE) 2 – 3 EVERY 3 – 4 WEEKS $250.00 SPIDER VEINS (LEGS) 3 – 4 EVERY 3 – 4 WEEKS $500.00 POIKILODERMA 3 – 4 EVERY 3 – 4 WEEKS $300.00-400.00 SCARS (1-5) 4 EVERY 3 – 4 WEEKS $150.00 STRETCH MARKS 4 EVERY 3 – 4 WEEKS $250.00 FACIAL REJUVENATION 4 EVERY 3 – 4 WEEKS $400.00 PSEUDOFOLLICULITIS BARBAE 3 – 4 EVERY 2 – 3 WEEKS $150.00 AMOUNT BILLED ACNE AND/OR ROSACEA *INSURANCE 4+ EVERY 2 WEEKS TO INSURANCE $180.00 IF PAID IN FULL ACNE AND/OR ROSACEA * CASH 4+ EVERY 1 –2 WEEKS AT TIME OF SERVICE $126.00 WARTS *INSURANCE 2+ EVERY 2 – 3 WEEKS --- WARTS * CASH 2+ EVERY 2 – 3 WEEKS $100.00 PSORIASIS $ (SMALL AREA) 6+ 1 WEEK $100.00 PSORIASIS - INSURANCE (PA REQ.) 6+ EVERY 2 WEEKS --- WOUND HEALING 3 – 6 1 – 2 TIMES A WEEK $150.00 TOENAIL FUNGUS (PER TOE) 1 – 4 EVERY 4 WEEKS $100.00 *Cash price for patients without insurance.
    [Show full text]
  • (2006.01) Published: A61K9/08
    ) ( (51) International Patent Classification: Published: A61K 31/05 (2006.01) A61P 1 7/02 (2006.01) — with international search report (Art. 21(3)) A61K9/08 (2006.01) A61P29/00 (2006.01) A61P 1 7/00 (2006.01) (21) International Application Number: PCT/AU20 19/05005 1 (22) International Filing Date: 24 January 2019 (24.01.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2018900226 24 January 2018 (24.01.2018) AU 62/621,225 24 January 2018 (24.01.2018) US 2018903600 25 September 2018 (25.09.2018) AU 62/736,052 25 September 2018 (25.09.2018) US (71) Applicant: BOTANIX PHARMACEUTICALS LTD [AU/AU]; 63 Aberdeen Street, Northbridge, Western Aus¬ tralia 6003 (AU). (72) Inventors: CALLAHAN, Matthew; One Kew Place, 150 Rouse Boulevard, Navy Yard Corporate Center, Philadel¬ phia, Pennsylvania 191 12 (US). THURN, Michael; 912 Kangaroobie Road, Kangaroobie, NSW 2800 (AU). (74) Agent: WRAYS PTY LTD; Level 7, 863 Hay Street, Perth, Western Australia 6000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Curriculum Vitae Clay J. Cockerell, M.D. Home
    CURRICULUM VITAE CLAY J. COCKERELL, M.D. HOME ADDRESS 4312 Arcady Avenue Dallas, Texas 75205 (214) 522-2610 WORK ADDRESS Cockerell & Associates-Dermpath Diagnostics Dermatopathology Laboratories 2330 Butler Street, Suite 115 Dallas, Texas 75235 Phone: (214) 530-5200, (800) 309-0000 Fax: (214) 530-5232 BIRTH DATE AND PLACE September 16, 1956, Houston, Texas MARITAL STATUS Married - Brenda West Cockerell Two children - Charles West Cockerell & Lillian Allene Cockerell COLLEGE EDUCATION 1974 – 1977 Texas Tech University Majors: Zoology, Microbiology, Chemistry No degree - entered Medical School via Early Decision Program GRADUATE EDUCATION 1977 - 1981 Baylor College of Medicine Degree - M.D. with honors, June 1981 POSTGRADUATE EDUCATION 1981-1982 Internship, Internal Medicine University of Washington Affiliated Hospitals, Seattle, Washington 1982-1985 Residency, Dermatology New York University Medical Center, New York, New York 1984-1985 Chief Resident, Dermatology New York University Medical Center, New York, New York 1985-1986 Fellowship, Dermatopathology New York University Medical Center, New York, New York OTHER TRAINING Sloan-Kettering Memorial Hospital, Pathology New York, New York Part-time clinical observer July 1986 - January 1987 Clay J. Cockerell, M.D. Updated 1/15/2018 Page 2 ACADEMIC APPOINTMENTS University of Texas Southwestern Medical Center Assistant Professor, Dermatology and Pathology, September 1988 - September 1992 Associate Professor, Dermatology and Pathology, September 1992 - September 1993 Clinical Associate Professor,
    [Show full text]
  • Pathological Investigation of Rosacea with Particular Regard Of
    A Clinico-Pathological Investigation of Rosacea with Particular Regard to Systemic Diseases Dr. Mustafa Hassan Marai Submitted in accordance with the requirements for the degree of Doctor of Medicine The University of Leeds School of Medicine May 2015 “I can confirm that the work submitted is my own and that appropriate credit has been given where reference has been made to the work of others” “This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement” May 2015 The University of Leeds Dr. Mustafa Hassan Marai “The right of Dr Mustafa Hassan Marai to be identified as Author of this work has been asserted by him in accordance with the Copyright, Designs and Patents Act 1988” Acknowledgement Firstly, I would like to thank all the patients who participate in my rosacea study, giving their time and providing me with all of the important information about their disease. This is helped me to collect all of my study data which resulted in my important outcome of my study. Secondly, I would like to thank my supervisor Dr Mark Goodfield, consultant Dermatologist, for his continuous support and help through out my research study. His flexibility, understanding and his quick response to my enquiries always helped me to relive my stress and give me more strength to solve the difficulties during my research. Also, I would like to thank Dr Elizabeth Hensor, Data Analyst at Leeds Institute of Molecular Medicine, Section of Musculoskeletal Medicine, University of Leeds for her understanding the purpose of my study and her help in analysing my study data.
    [Show full text]
  • A Dissertation on CLINICO EPIDEMIOLOGICAL STUDY of FACIAL DERMATOSES AMONG ADULTS
    A Dissertation on CLINICO EPIDEMIOLOGICAL STUDY OF FACIAL DERMATOSES AMONG ADULTS Dissertation submitted to THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY CHENNAI-600032 With partial fulfillment of the requirements for the award of M.D.DEGREE IN DERMATOLOGY, VENEREOLOGY AND LEPROLOGY (BRANCH - XX) REG. No. 201730201 COIMBATORE MEDICAL COLLEGE AND HOSPITAL COIMBATORE MAY 2020 DECLARATION I Dr . MANIVANNAN . M solemnly declare that the dissertation entitled “CLINICO EPIDEMIOLOGICAL STUDY OF FACIAL DERMATOSES AMONG ADULTS ” is a bonafide work done by me at Coimbatore Medical College Hospital during the year June 2018 to May 2019 under the guidance & supervision of Dr. M. KARUNAKARAN M.D., (DERM) Professor& Head of Department, Department of Dermatology, Coimbatore Medical College & Hospital. The dissertation is submitted to Dr. MGR Medical University towards partial fulfillment of requirement for the award of MD degree branch XX Dermatology, Venereology and Leprology. PLACE: Dr. MANIVANNAN .M DATE: CERTIFICATE This is to certify that the dissertation entitled “CLINICO EPIDEMIOLOGICAL STUDY OF FACIAL DERMATOSES AMONG ADULTS” is a bonafide original work done by Dr. MANIVANNAN.M. Post graduate student in the Department of Dermatology, Venereology and Leprology, Coimbatore Medical College Hospital, Coimbatore under the guidance of Dr. M. KARUNAKARAN M.D., (DERM), Professor and HOD of Department, Department of Dermatology, Coimbatore Medical College Hospital, Coimbatore in partial fulfillment of the regulations for the Tamilnadu DR.M.G.R Medical University, Chennai towards the award of MD., degree (Branch XX.) in Dermatology, Venereology and Leprology. Date : GUIDE Dr. M. KARUNAKARAN M.D., (DERM) Professor & HOD, Department of Dermatology, Coimbatore Medical College & Hospital. Date : Dr.
    [Show full text]